Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.

Saved in:

Bibliographic Details
Title:	Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.
Authors:	Liu W; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China., Huo G; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China., Chen P; Department of Thoracic Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.; National Clinical Research Center for Cancer, Tianjin, China.; Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin, China.; Tianjin's Clinical Research Center for Cancer, Tianjin, China.
Source:	Frontiers in public health [Front Public Health] 2024 Feb 15; Vol. 12, pp. 1213318. Date of Electronic Publication: 2024 Feb 15 (Print Publication: 2024).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Frontiers Editorial Office Country of Publication: Switzerland NLM ID: 101616579 Publication Model: eCollection Cited Medium: Internet ISSN: 2296-2565 (Electronic) Linking ISSN: 22962565 NLM ISO Abbreviation: Front Public Health Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2296-2565
DOI:	10.3389/fpubh.2024.1213318